Overview

Sorafenib for Hepatopulmonary Syndrome

Status:
Terminated

Trial end date:
2018-01-01

Target enrollment:

Participant gender:

Summary

The main purpose of this clinical trial is to determine the safety and effects of the study drug, sorafenib, in adults diagnosed with hepatopulmonary syndrome (HPS). The study will evaluate how well the drug is tolerated and its effect on the level of oxygen in the blood and the function of the lung vessels.

Phase:

Phase 2

Details

Lead Sponsor:

University of Pennsylvania

Collaborator:

National Heart, Lung, and Blood Institute (NHLBI)

Treatments:

Niacinamide
Sorafenib